Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

The differential diagnosis of neurological diseases by fractionating electrophoretically the CSF gamma-globulins.
Genome, epigenome and RNA sequences of monozygotic twins discordant for multiple sclerosis.
Novel MS Drugs Advance
The value of qualitative and quantitative assessment of lesion to cerebral cortex signal ratio on double inversion recovery sequence in the differentiation of demyelinating plaques from non-specific T2 hyperintensities.
Masitinib in Patients with Primary Progressive Multiple Sclerosis (PPMS) or Relapse-Free Secondary Multiple Sclerosis (SPMS)
Changes in Blood B Cell-Activating Factor (BAFF) Levels in Multiple Sclerosis: A Sign of Treatment Outcome.
Adherence to Disease Modifying Drugs among Patients with Multiple Sclerosis in Germany: A Retrospective Cohort Study.
Microglia across the lifespan: from origin to function in brain development, plasticity and cognition.
The Australian Multiple Sclerosis (MS) Immunotherapy Study: A Prospective, Multicentre Study of Drug Utilisation Using the MSBase Platform.
Long-term efficacy and safety of transanal irrigation in multiple sclerosis.
Breastfeeding and multiple sclerosis relapses: a meta-analysis.
Synthetic Biologics announces issuance of U.S. patent covering combination of estriol and Copaxone® for multiple sclerosis
Pathogenic aquaporin-4 reactive T cells are sufficient to induce mouse model of neuromyelitis optica.
Antibody to α4 integrin suppresses natural killer cells infiltration in central nervous system in experimental autoimmune encephalomyelitis.
Dendritic cell, monocyte and T cell activation and response to glatiramer acetate in multiple sclerosis.
From High- to Low-Frequency Administered Interferon-Beta for Multiple Sclerosis: A Multicenter Study.
Phase IV, Rater-blinded, Randomized Study, Comparing the Effects of 250 mg of Betaseron With 20 mg of Copaxone in Patients With the Relapsing-remitting or Clinically Isolated Forms of Multiple Sclerosis Using 3 Tesla MRI With Triple-dose Gadolinium
Covis Pharma to Acquire U.S. Rights from Sanofi for Nilandron®, Plaquenil®, Rilutek®, Uroxatral®, and Kayexalate®
European Commission approves Genzyme’s multiple sclerosis treatment Lemtrada™ (alemtuzumab)
Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.
The employment concerns of Americans with multiple sclerosis: Perspectives from a national sample.
Sex hormones and multiple sclerosis: another informative failure.
The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group.
Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate's protective effect in EAE.
Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action.

Pages